

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

**FORM 6-K**

**Report of Foreign Private Issuer  
Pursuant to Rule 13a-16 or 15d-16  
under the Securities Exchange Act of 1934**

**For the Month of September 2012**

**CAMTEK LTD.**

(Translation of Registrant's Name into English)

**Ramat Gavriel Industrial Zone  
P.O. Box 544  
Migdal Haemek 23150  
ISRAEL**

(Address of Principal Corporate Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities and Exchange Act of 1934.

Yes  No

---

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CAMTEK LTD.  
(Registrant)

By: /s/ Moshe Eisenberg

\_\_\_\_\_  
Moshe Eisenberg,  
*Chief Financial Officer*

Dated: September 24, 2012

**CAMTEK LTD.**

Moshe Eisenberg, CFO  
Tel: +972 4 604 8308  
Mobile: +972 54 900 7100  
[moshee@camtek.co.il](mailto:moshee@camtek.co.il)

**INTERNATIONAL INVESTOR  
RELATIONS**

CCG Investor Relations  
Ehud Helft / Kenny Green  
Tel: (US) 1 646 201 9246  
[camtek@ccgisrael.com](mailto:camtek@ccgisrael.com)

**FOR IMMEDIATE RELEASE****CAMTEK APPOINTS MR. MOSHE BARUCH AS VP  
TECHNOLOGIES AND DR. BOAZ NITZAN AS VP DMD  
PRODUCT LINE**

---

**MIGDAL HAEMEK, Israel – September 24, 2012 – Camtek Ltd. (NASDAQ and TASE: CAMT)** (“Camtek”), announced today the appointment of Mr. Moshe Baruch as VP Technologies and Dr. Boaz Nitzan as VP of the DMD (Digital Material Deposition) product line.

Mr. Moshe Baruch joins Camtek after 14 years with publically listed semiconductor capital equipment company, KLA-Tencor, where he held various research and development positions and served as the head of R&D of KLA-Tencor Israel for the past six years. Prior to that, Moshe held several R&D leadership positions at large Israeli-based companies, developing multi-disciplinary products for the defense industry, including Rafael, Elta, and Tadiran.

Dr. Boaz Nitzan holds Ph.D. in Physical Chemistry and brings over 13 years of executive level management with vast experience in the Printing Industry in companies such as Scitex Vision, Aprion Digital and Scitex. Prior to joining Camtek, Dr. Nitzan held several executive positions, leading cross-functional research and development of novel technology products. He served as CEO at AMS Technologies, Vice President of R&D and Production at BPT - Bio Prior Technology and Vice President R&D at Power Paper.

**Mr. Roy Porat, Camtek’s Chief Executive Officer, commented,** “Camtek’s new product segments, intended to support Camtek’s growth and penetration into new markets, present many challenges in terms of dedicated technologies, thus requiring highly focused expertise and managerial experience. We are very happy to have Mr. Baruch and Dr. Nitzan on board with their remarkable proven abilities and experience, and believe that they will each make a tremendous contribution to Camtek in their new positions.”

**ABOUT CAMTEK LTD.**

Camtek Ltd. provides automated and technologically advanced solutions dedicated to enhancing production processes and increasing yields, enabling and supporting customer’s latest technologies in the Semiconductors, Printed Circuit Boards (PCB) and IC Substrates industries.

Camtek addresses the specific needs of these interconnected industries with dedicated solutions based on a wide and advanced platform of technologies including intelligent

imaging, image processing, adaptive ion milling (AIM) and digital material deposition (DMD). Camtek's solutions range from micro-to-nano by applying its technologies to the industries' specific requirements.

This press release is available at [www.camtek.co.il](http://www.camtek.co.il).

*This press release may contain projections or other forward-looking statements regarding future events or the future performance of the Company. These statements are only predictions and may change as time passes. We do not assume any obligation to update that information. Actual events or results may differ materially from those projected, including as a result of changing industry and market trends, reduced demand for our products, the timely development of our new products and their adoption by the market, increased competition in the industry, intellectual property litigation, price reductions as well as due to risks identified in the documents filed by the Company with the SEC.*

## Consolidated Balance Sheets

(In thousands)

	June 30, 2012	December 31, 2011
	U.S. Dollars (In thousands)	
<b>Assets</b>		
<b>Current assets</b>		
Cash and cash equivalents	13,833	22,185
Short-term deposits	7,800	4,100
Accounts receivable, net	31,115	24,451
Inventories	25,794	24,355
Due from affiliates	331	388
Other current assets	3,983	3,357
Deferred tax asset	110	110
Total current assets	<u>82,966</u>	<u>79,946</u>
Fixed assets, net	<u>14,472</u>	<u>14,577</u>
Long term inventory	2,700	1,954
Deferred tax asset	132	132
Other assets, net	304	304
Intangible assets, net *	3,986	4,191
Goodwill	3,653	3,653
	<u>10,775</u>	<u>10,234</u>
<b>Total assets</b>	<b><u>108,213</u></b>	<b><u>104,757</u></b>
<b>Liabilities and shareholders' equity</b>		
<b>Current liabilities</b>		
Short term bank loans	3,000	3,000
Accounts payable – trade	11,429	6,773
Long term bank loans – current portion	1,700	1,700
Due to affiliates	196	-
Other current liabilities	20,228	21,568
Total current liabilities	<u>36,553</u>	<u>33,041</u>
<b>Long term liabilities</b>		
Long term bank loans	1,242	2,092
Liability for employee severance benefits	645	652
Other long term liabilities *	8,728	9,039
	<u>10,615</u>	<u>11,783</u>
Total liabilities	<u>47,168</u>	<u>44,824</u>
<b>Commitments and contingencies</b>		
<b>Shareholders' equity</b>		
Ordinary shares NIS 0.01 par value, authorized 100,000,000 shares, 31,986,005 issued as June 30, 2012 and 31,810,340 as of December 31, 2011, outstanding 29,893,629 as of June 30, 2012 and 29,717,964 as of December 31, 2011	133	133
Additional paid-in capital	61,217	61,014
Accumulated income	1,593	684
	<u>62,943</u>	<u>61,831</u>
Treasury stock, at cost (2,092,376 as of June 30, 2012 and December 31, 2011)	<u>(1,898)</u>	<u>(1,898)</u>
Total shareholders' equity	<u>61,045</u>	<u>59,933</u>
<b>Total liabilities and shareholders' equity</b>	<b><u>108,213</u></b>	<b><u>104,757</u></b>

(\*) Relates to Printar and SELA acquisitions

## Consolidated Statements of Operations

(in thousands, except share data)

	Six Months ended June 30,		Three Months ended June 30,		Year ended December 31,
	2012	2011	2012	2011	2011
	U.S. dollars		U.S. dollars		U.S. dollars
<b>Revenues</b>	<b>43,211</b>	56,248	<b>25,033</b>	28,778	107,028
Cost of revenues	<b>23,506</b>	30,415	<b>12,961</b>	15,752	59,588
<b>Gross profit</b>	<b>19,705</b>	25,833	<b>12,072</b>	13,026	47,440
Research and development costs	<b>6,645</b>	7,360	<b>3,320</b>	3,581	14,077
Selling, general and administrative expenses	<b>*10,923</b>	12,707	<b>*5,488</b>	6,644	24,341
	<b>17,568</b>	20,067	<b>8,808</b>	10,225	38,418
<b>Operating income</b>	<b>2,137</b>	5,766	<b>3,264</b>	2,801	9,022
Financial expenses, net	<b>(986)</b>	(769)	<b>(854)</b>	(361)	(2,900)
<b>Income before income taxes</b>	<b>1,151</b>	4,997	<b>2,410</b>	2,440	6,122
Income tax	<b>(242)</b>	(370)	<b>(144)</b>	(234)	(744)
<b>Net income</b>	<b>909</b>	4,627	<b>2,266</b>	2,206	5,378
<b>Net income per ordinary share:</b>					
<b>Basic</b>	<b>0.03</b>	0.16	<b>0.08</b>	0.07	0.18
<b>Diluted</b>	<b>0.03</b>	0.15	<b>0.08</b>	0.07	0.18
<b>Weighted average number of ordinary shares outstanding:</b>					
<b>Basic</b>	<b>29,803</b>	29,487	<b>29,881</b>	29,641	29,577
<b>Diluted</b>	<b>30,003</b>	30,017	<b>30,013</b>	29,973	30,009

(\*) Including income of approximately 1 million dollars related to a settlement with a former service provider of the company.

**Camtek Ltd.**

**Reconciliation of GAAP to Non-GAAP results**

(In thousands, except share data)

	Six Months ended June 30,		Three Months ended June 30,		Year ended December 31,
	2012	2011	2012	2011	2011
	U.S. dollars		U.S. dollars		U.S. dollars
<b>Reported net income attributable to Camtek Ltd. on GAAP basis</b>	<b>909</b>	4,627	<b>2,266</b>	2,206	5,378
Acquisition of Sela and Printar related expenses (1)	<b>1,170</b>	1,138	<b>596</b>	575	2,377
Inventory write –downs (2)	-	-	-	-	685
Share-based compensation	<b>205</b>	235	<b>103</b>	126	416
Shelf registration expenses	<b>94</b>	-	-	-	-
<b>Non-GAAP net income</b>	<b>2,378</b>	6,000	<b>2,965</b>	2,907	8,856
<b>Non –GAAP net income per share , basic and diluted</b>	<b>0.08</b>	<b>0.20</b>	<b>0.10</b>	<b>0.10</b>	0.30
<b>Gross margin on GAAP basis</b>	<b>45.6%</b>	45.9%	<b>48.2%</b>	45.3%	44.3%
<b>Reported gross profit on GAAP basis</b>	<b>19,705</b>	25,833	<b>12,072</b>	13,026	47,440
Acquisition of Sela and Printar related expenses ( 1)	<b>150</b>	160	<b>75</b>	80	331
Inventory write –downs (2)	-	-	-	-	685
Share-based compensation	<b>50</b>	54	<b>25</b>	29	97
<b>Non- GAAP gross margin</b>	<b>46.2%</b>	46.3%	<b>48.6%</b>	45.6%	45.4%
<b>Non-GAAP gross profit</b>	<b>19,905</b>	26,047	<b>12,172</b>	13,135	48,553
<b>Reported operating income attributable to Camtek Ltd. on GAAP basis</b>	<b>2,137</b>	5,766	<b>3,264</b>	2,801	9,022
Acquisition of Sela and Printar related expenses (1)	<b>150</b>	160	<b>75</b>	80	331
Inventory write-downs (2)	-	-	-	-	685
Share-based compensation	<b>205</b>	235	<b>103</b>	126	416
Shelf registration expenses	<b>94</b>	-	-	-	-
<b>Non-GAAP operating income</b>	<b>2,586</b>	6,161	<b>3,442</b>	3,007	10,454

(1) During the three and six months ended June 30, 2012 and 2011 and the twelve months ended December 31, 2011, the Company recorded acquisition expenses of \$0.6 million, \$1.2 million,

\$0.6 million, \$1.1 million and \$2.4 million, respectively, consisting of: (1) inventory written-up to fair value in purchase accounting charges of \$0 million, \$0 million, \$0.01 million, \$0.02 million and \$0.02 million, respectively. These amounts are recorded under cost of revenues line item. (2) Revaluation adjustments of \$0.5 million, \$1.0 million, \$0.5 million, \$1.0 million and \$2.0 million, respectively, of contingent consideration and certain future liabilities recorded at fair value. These amounts are recorded under finance expenses line item and (3) \$0.07 million, \$0.15 million, \$0.07 million, \$0.14 million and \$0.3 million, respectively, with respect to amortization of intangible assets acquired recorded under cost of revenues line item.

- (2) During the three months and six months ended June 30, 2012 and 2011, and the twelve months ended December 31, 2011, the Company recorded inventory write down in the amount of \$0 million, \$0 million, \$0 million, \$0 million, and \$0.7 million, respectively.